Gallant raises $15m to advance stem cell therapies for pets

Pet longevity biotech is developing ready-to-use doses of allogeneic stem cell therapeutics targeting chronic diseases in dogs and cats.
Animal health biotech Gallant Therapeutics has secured more than $15 million in Series A financing to advance its “off-the-shelf” stem cell therapies for pets. The clinical-stage biotechnology company is developing ready-to-use doses of allogeneic stem cell therapeutics designed to address the root causes of several major diseases in pets.

Gallant has a pipeline of stem cell therapies targeting chronic diseases prevalent in dogs and cats, including osteoarthritis, chronic kidney disease, and atopic dermatitis. The new funding will be used, in part, to support Gallant’s efforts to expedite conditional FDA approval of its lead candidate, an allogeneic stem cell therapy targeting Feline Chronic Gingivostomatitis (FCGS), supported by positive outcomes from pilot studies and the initiation of the JEDI pivotal study in December.

Gallant says that achieving conditional FDA approval would be a pivotal step, not only for its FCGS program, but also in de-risking the company’s core stem cell therapeutic platform, potentially expediting market access for other pipeline programs.

“We have made unprecedented progress this past year, hitting significant clinical, regulatory, and manufacturing milestones,” said Dr Linda Black, CEO of Gallant. “This investment allows us to leverage our early-stage successes, extending beyond FCGS, to bring a diverse range of therapies to the broader pet market.”

The funding round was led by BOLD Capital, with participation from new investors Digitalis Ventures and Hill Creek Partners. Cindy Cole of Digitalis Ventures joins Gallant as a board observer.

“Bringing a new class of therapies to the market is exciting and requires exceptional talent, technology, and manufacturing capabilities,” said Cole. “Gallant has all of that. We look forward to partnering with them to realize the broad clinical potential of their validated technologies and redefine standards in veterinary care.”

Gallant raises $15m to advance stem cell therapies for pets